MadeMed

MadeMed keeps the process simple. You start by choosing a weight loss treatment, such as injectable semaglutide, injectable tirzepatide, oral semaglutide, or oral tirzepatide. You then answer a short online quiz, which includes questions about how much weight you want to lose, whether you have used GLP-1 medication before, and whether you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The good part is that the experience feels quick and easy. The concern is that a 3-question quiz may feel too brief for a prescription weight loss medication. You should expect a proper medical review before approval, especially around your BMI, health history, current medications, pregnancy status, allergies, previous GLP-1 use, and side effects.

After the quiz, a doctor reviews your information and decides whether a prescription is appropriate. If it is, the doctor prescribes within 24 hours, then the medication ships to your door. For injectables, you inject weekly, and for oral tablets, you take 1 tablet daily under your tongue.

Take the free 2-minute quiz now & see if you qualify

MadeMed positions injectable semaglutide as a treatment associated with 15–20% average body weight loss and injectable tirzepatide as a treatment associated with 20–25% average body weight loss. These are strong claims, so you should treat them as general expectations rather than guaranteed personal results.

Your results depend on your starting weight, dose, tolerance, lifestyle, consistency, and medical profile. New injectable semaglutide patients typically start at 0.25 mg weekly, with increases every 4 weeks or later – oral semaglutide starts at 1 mg daily, with increases up to 6 mg. Oral tirzepatide starts at 3 mg daily, with steps up to 7 mg.

The application method depends on your plan. Injectable options are taken weekly with a small syringe. Oral options are sublingual tablets that dissolve under your tongue.

MadeMed offers more than just medication. The FAQ states that you can opt into personalized meal plans, recipes, shopping lists, and exercise programs tailored to your goals, dietary preferences, and progress.

You also get flat pricing across doses, which is one of MadeMed’s better selling points. Many GLP-1 programs become more expensive as your dose increases. MadeMed’s approach means your doctor can adjust your dose without changing your monthly displayed price.

The brand also highlights free overnight shipping, discreet packaging, injection supplies for injectable plans, and a medical evaluation.

Take the free 2-minute quiz now & see if you qualify

MadeMed’s website is clean, modern, and easy to follow. It’s easy to compare oral and injectable options, and the pricing pages clearly show dose levels. The “How It Works” section is also simple: answer questions, doctor review, medication ships, and then you begin treatment.

The checkout page is where clarity becomes very important. Injectable semaglutide appears as $239/month, but the order summary shows $239 × 3 = $717 for quarterly billing. Another semaglutide screen shows $199/month with 6-month billing at $1,194. Oral semaglutide shows $179/month, billed $1,074 every 6 months.

You can pause your subscription, and billing stops immediately. It also says you’ll receive a reminder after your pause period ends and that you can extend it at any time. You’ll receive an email 7 days before every charge, with the exact amount and options to pause, skip, or cancel.

This is reassuring because GLP-1 treatment often requires dose adjustments, side-effect management, and long-term planning. Your dose only changes when you request it, with care team review and approval before increases.

Every consultation is reviewed by a board-certified physician licensed in your state, and MadeMed’s platform is HIPAA-compliant. They also work with licensed, accredited U.S. compounding pharmacies.

This matters because compounded GLP-1 products require extra transparency. The FDA has warned telehealth companies against misleading claims about compounded GLP-1 drugs, and Reuters reported that regulators have emphasized that compounded versions are not FDA-approved in the same way as branded drugs.

MadeMed includes an important safety question about thyroid cancer and MEN2 in the quiz, but the intake should ideally include additional medical screening before payment or approval.